ESTRO 36 Abstract Book

S755 ESTRO 36 _______________________________________________________________________________________________

scales showed a variable course but maxed or at least showed a recovery 12 weeks after RT. Symptoms with a high mean symptom score (> 40) were fatigue, dyspnoea and coughing. Insomnia, peripheral neuropathia, appetite loss, dyspnoea (from QLQ-LC13) and all parameters for pain had an intermediate mean score (10 – 40). There were low mean scores of fewer than 10 for nausea and vomiting, diarrhoea, sore mouth and haemoptysis. The GLM revealed no statistically significant difference for any QLQ-C30 parameter over time. For the QLQ-LC13 statistically significant differences over time were found for the peripheral neuropathy (p = 0,011) and the dysphagia (p = 0,034). There was a highly significant correlation between the clinical dysphagia and the dysphagia scores (p < 0,005). The correlation between clinical RP and the scores for dyspnoea and coughing was significant at some follow- up appointments. The EORTC QLQ-C30 and QLQ-LC13 scores did not prove to have a significant influence on the overall survival or distant and local failure. Conclusion 12 weeks after RT the scores of the QLQ-C30 functional scales showed the highest scores or at least a temporary recovery. The symptom scales accurately reflected the common symptoms and treatment related toxicities. There was a significant correlation between clinical dysphagia and pneumonitis and associated QoL scores. QoL did not prove to be a significant predictor for survival or distant and local control. EP-1413 IORT for treatment of recurrent tumors - A single institution analysis. T.M. Coelho 1 , R.C. Fogaroli 1 , A.C.A. Pellizzon 1 , D.G. Castro 1 , G.R.M. Gondim 1 , M.L.G. Silva 1 , M.J. Chen 1 , A.A. Ambrosio 1 1 Accamargo cancer center, Radiotherapy, Sao Paulo sp, Brazi Purpose or Objective The incidence of recurrent retroperitoneal or pelvic tumors (rRPT) varies from 20% to 77% in literature and requires a multidisciplinary approach. Local control (LC) with isolated salvage surgical resection is dismal, and intraoperative radiotherapy (IORT) can be considered an adjuvant treatment option for selected cases, in special those with previous course of radiation. This study assessed the feasibility, efficacy and morbidity of IORT as adjuvant treatment of rRPT who underwent to salvage surgical resection. Material and Methods 41 patients with non-metastatic and isolated (one anatomic site) rRPT were treated from 2004 to 2015. All patients were treated with intraoperative electron beam, except one patient who was treated with intraoperative high dose rate brachytherapy. The mean doses were 16 Gy (range 10-21) and 14Gy (range 9-20) for patients without and with previous external beam radiation therapy (EBRT), respectively. The dose was delivered with a 2cm safe margin around the tumor bed. Seventeen (39%) patients had additional EBRT (mean dose 45 Gy) after surgery and IORT. Median survival times were calculated using Kaplan-Meier analysis and differences in survival between groups were tested using log-rank test. The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) for potential predictors of LC, overall survival(OS) and disease-specific survival(DSS). A difference was considered statistically significant if Twenty-two (54%) patients had pelvic lesions and 19(46%) had retroperitoneal disease. In addition, 3 patients had a second course of RTIO for a second recurrent tumor in different anatomical site, 31 patients (82%) had resection R0 and 8 patients (18%) had resection R1. The most common recurrent tumors were colorectal cancer p≤0,05. Results

Conclusion Chemo-IMRT is feasible and well tolerated with acceptable outcomes even in the subset of elderly patients with locally advanced disease.

Electronic Poster: Clinical track: Other

EP-1412 Quality of life of patients after high dose radiation therapy for thoracic carcinomas C. Schröder 1 , R. Engenhart-Cabillic 2 , A. Buchali 3 1 Universität Giessen, Klinik für Strahlentherapie und Radioonkologie- Universitätsklinikum Giessen und Marburg, Giessen, Germany 2 Universität Marburg, Klinik für Strahlentherapie und Radioonkologie- Universitätsklinikum Giessen und Marburg, Marburg, Germany 3 Ruppiner Kliniken GmbH, Klinik für Strahlentherapie und Radioonkologie, Neuruppin, Germany Purpose or Objective Quality of life (QoL) is an important factor in patient care. In this analysis we focused on QoL before and after radio- (chemo-)therapy (RCT) in patients with thoracic carcinomas and its influence on clinical follow up, survival and the correlation with treatment related toxicities. Material and Methods 81 curatively treatable patients with intrathoracical carcinoma (NSCLC, SCLC, esophageal carcinoma) were included in this analysis. They received radio-(chemo-) therapy. Patients with NSCLC were treated with 74 Gy, patients with SCLC with 60 Gy and those with esophageal carcinomas with 66 Gy. Eligible patients received chemotherapy according to intradepartmental standards. For the analysis of the QoL the EORTC QLQ-C30 and the EORTC QLQ-LC13 were used. QoL data was collected before radiation treatment, 6 weeks, 12 weeks, 6 month and 12 month after RT. Additionally factors were analyzed, including clinical outcome, survival, treatment induced side effects. Results The median follow up was 34,5 weeks. In total 49,4 % of patients had a complete or partial remission and 16,0 % a stable local disease. Local failure occurred in 24,7 % of patients. Distant failure occurred in 44,4 % of patients. Severe dysphagia occurred in up to 9 % of patients, up to 50 % experienced mild dysphagia. The overall rates for RT induced pneumonitis (RP) were low with a maximum of 8 % 12 weeks after RT. The median survival time was 34 weeks with a range from 1 to 220 weeks. All functional